Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease

VX-950 is a potent, selective, peptidomimetic inhibitor of the hepatitis C virus (HCV) NS3-4A serine protease, and it demonstrated excellent antiviral activity both in genotype 1b HCV replicon cells (50% inhibitory concentration [IC(50)] = 354 nM) and in human fetal hepatocytes infected with genotyp...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Perni, Robert B., Almquist, Susan J., Byrn, Randal A., Chandorkar, Gurudatt, Chaturvedi, Pravin R., Courtney, Lawrence F., Decker, Caroline J., Dinehart, Kirk, Gates, Cynthia A., Harbeson, Scott L., Heiser, Angela, Kalkeri, Gururaj, Kolaczkowski, Elaine, Lin, Kai, Luong, Yu-Ping, Rao, B. Govinda, Taylor, William P., Thomson, John A., Tung, Roger D., Wei, Yunyi, Kwong, Ann D., Lin, Chao
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology 2006
Materias:
Antiviral Agents
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC1426435/
https://ncbi.nlm.nih.gov/pubmed/16495249
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.50.3.899-909.2006
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares